The present study demonstrated that DCs treated with IL‐37 and TnI display a tolerogenic phenotype and that IL‐37 and IL‐37–treated TnI‐loaded tDCs are likely to play an immunoprotective role during the post‐MI remodeling, suggesting that IL‐37 or adoptive transfer of IL‐37 plus TnI–treated tDCs may represent a novel therapeutic strategy for ventricular remodeling after MI. This evidence concerns the gene IL37 and myocardial infarction.